Tucatinib Continuation Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
SMP-656 for HER2-Positive Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- NA
Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
- Status
- RECRUITING
- Phase
- PHASE2
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3